Leila Alland Sells 4,000 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) insider Leila Alland sold 4,000 shares of the company’s stock in a transaction dated Monday, June 7th. The shares were sold at an average price of $33.60, for a total transaction of $134,400.00. Following the transaction, the insider now owns 4,000 shares in the company, valued at approximately $134,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Leila Alland also recently made the following trade(s):

  • On Friday, May 7th, Leila Alland sold 4,000 shares of PMV Pharmaceuticals stock. The shares were sold at an average price of $34.83, for a total transaction of $139,320.00.
  • On Wednesday, April 7th, Leila Alland sold 4,000 shares of PMV Pharmaceuticals stock. The shares were sold at an average price of $33.86, for a total transaction of $135,440.00.

PMVP opened at $32.73 on Friday. PMV Pharmaceuticals, Inc. has a 52-week low of $26.38 and a 52-week high of $63.22. The firm’s 50-day moving average is $33.44. The firm has a market capitalization of $1.47 billion and a P/E ratio of -13.64.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its quarterly earnings results on Friday, May 14th. The company reported ($0.26) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.26). On average, sell-side analysts forecast that PMV Pharmaceuticals, Inc. will post -1.22 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. E Fund Management Co. Ltd. acquired a new position in PMV Pharmaceuticals in the 1st quarter worth approximately $35,000. Royal Bank of Canada increased its holdings in PMV Pharmaceuticals by 163.4% in the 1st quarter. Royal Bank of Canada now owns 1,093 shares of the company’s stock worth $36,000 after buying an additional 678 shares during the period. Citigroup Inc. acquired a new position in PMV Pharmaceuticals in the 4th quarter worth approximately $158,000. Strs Ohio acquired a new position in PMV Pharmaceuticals in the 4th quarter worth approximately $202,000. Finally, Credit Suisse AG acquired a new position in PMV Pharmaceuticals in the 4th quarter worth approximately $248,000. Institutional investors own 88.63% of the company’s stock.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function.

Recommended Story: What do I need to know about analyst ratings?

Insider Buying and Selling by Quarter for PMV Pharmaceuticals (NASDAQ:PMVP)

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.